Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma

Cancer

Volumn 107, Issue 4, 2006, Pages 686-695

  Weigert, Oliver ^a   Illidge, Tim ^b   Hiddemann, Wolfgang ^a   Dreyling, Martin ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Autologous stem cell transplantation; B cell non Hodgkin lymphoma; Consolidation therapy; Radioimmunotherapy

Indexed keywords

CD20 ANTIGEN; CHIMERIC ANTIBODY; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131;

ALGORITHM; ANEMIA; ARTICLE; ASTHENIA; B CELL LYMPHOMA; BLOOD TOXICITY; CHILL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA; LYMPHOMA; MALIGNANT TRANSFORMATION; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; META ANALYSIS; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RELAPSE; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; HUMANS; LYMPHOMA; PRACTICE GUIDELINES; RADIOIMMUNOTHERAPY; YTTRIUM RADIOISOTOPES;

EID: 33747260159     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22066     Document Type: Article

References (63)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
3. Jaffe ES, Harris NL, Stein H. Tumours of the Haemopoitic and Lymphoid Tissues. Lyon: IARC Press; 2001.
4. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993;20 (Suppl. 5):75-88.
5. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23:5019-5026.
6. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
7. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-276.
8. Hiddemann W, Kneba M, Dreyling M, et al. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone: Results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood. 2005;106:3725-3732.
9. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-1423.
10. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German low-grade lymphoma study group. Blood. 2004;104:3064-3071.
11. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective randomized trial of the German low-grade lymphoma study group. Blood. 2004;104:2667-2674.
12. Lenz G, Dreyling M, Schiegnitz E, et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: Results of a prospective randomized trial of the German low grade lymphoma study group. J Clin Oncol. 2004;22:4926-4933.
13. Johansson L, Carlsson J, Nilsson K. Radiosensitivity of human B-lymphocytic lymphomas in vitro. Int J Radiat Biol Relat Stud Phys Chem Med. 1982;41:411-420.
14. Safwat A. The role of low-dose total body irradiation in treatment of non-Hodgkin's lymphoma: A new look at an old method. Radiother Oncol. 2000;56:1-8.
15. Press OW. Radioimmunotherapy for non-Hodgkin's lymphomas: A historical perspective. Semin Oncol. 2003;30 (Suppl. 4):10-21.
16. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood. 1984;63:1424-1433.
17. Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987;69:584-591.
18. Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol. 1985;135:973-979.
19. Connors JM. Radioimmunotherapy-hot new treatment for lymphoma. N Engl J Med. 2005;352:496-498.
20. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449.
21. Rao AV, Akabani G, Rizzieri DA. Radioimmunotherapy for non-Hodgkin's lymphoma. Clin Med Res. 2005;3:157-165.
22. Grillo-Lopez AJ. Zevalin: The first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther. 2002;2:485-493.
23. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43:267-272.
24. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-3803.
25. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
26. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood. 2002;99:4336-4342.
27. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262-3269.
28. Morschhauser F, Huglo D, Martinelli G, Paganelli G, Zinzani PL, Illidge T. Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large cell b-cell lymphoma not appropriate for autologous stem cell transplantation: Results of an open-label phase II trial. Blood. 2004;104:107.
29. 90Y) ibritumomab tiuxetan (Zevalin®) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL). Blood. 2005;106(11) Abstract 2452.
30. Wiseman GA, Leigh B, Erwin WD, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer. 2002;94 (Suppl. 4):1349-1357.
31. 90Y IT) in patients with CD20+ non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol. 2005;23 (Suppl. 16) Abstract 2547.
32. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials. J Nucl Med. 2003;44:465-474.
33. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol. 2001;39:181-194.
34. 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res. 1999;5 (Suppl. 10):S3281-S3286.
35. 90Yttrium ibritumomab tiuxetan (Zevalin®) after autologous stem cell transplant (asct) in patients with non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol. 2005;23 (Suppl. 16) Abstract 6669.
36. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:1263-1270.
37. Czuczman M, Witzig T, Gaston I, et al. Zevalin is not associated with an increased incidence of secondary myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). Blood. 2002;100(11) Abstract 1386.
38. Wiseman G, Leigh B, Witzig T. Radiation exposure is very low to the family members of patients treated with yttrium-90 Zevalin anti-CD20 monoclonal antibody therapy for lymphoma. Eur J Nucl Med. 2001;28:1198.
39. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: The coming of age of radioimmunotherapy. Crit Rev Oncol Hematol. 2001;39:195-201.
40. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study. Blood. 2004;103:4429-4431.
41. 90Y-It) in children with recurrent/refractory CD20 positive lymphoma: A cog phase I consortium study. Blood. 2005;106(11) Abstract 2248.
42. Emmanouilides C, Murray JL, Vo K, Witzig T, Darif M, Schilder RJ. Earlier yttrium-90 ibritumomab tiuxetan (Zevalin) treatment in patients with previously-treated B-cell non-Hodgkin's lymphoma: Higher response rates and longer durations of response. Hematol J. 2004;5 (Suppl. 2):S8.
43. 90Y) ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma. Blood. 2004;104(11) Abstract 2633.
44. Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3885-3890.
45. Schilder RJ, Ansell SM, Pieslor PC, Gordon LI, Emmanouilides C, Czuczman M. Subsequent therapy for non-Hodgkin's lymphoma is feasible after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan (Zevalin). Hematol J. 2004;5 (Suppl. 2):S7.
46. Wiseman G, Colgan JP, Inwards DJ, Micallef IN, Gansen DN, Porrata LF. Yttrium-90 Zevalin phase I sequential dose radioimmunotherapy trial of patients with relapsed low grade and follicular B-cell lymphoma (NHL): Preliminary results. Blood. 2002;100 Abstract 1387.
47. Winter JN, Gascoyne RD, Van Besien K. Low-grade lymphoma. Hematology (Am Soc Hematol Educ Program). 2004;11:203-220.
48. 90Y) ibritumomab tiuxetan (Zevalin®) in patients with relapsed or refractory mantle cell lymphoma (mcl) after/not appropriate for autologous stem cell transplantation (asct)- A phase II trial of the European mcl network. Blood. 2005;106(11) Abstract 4786.
49. 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: Update of a minnie pearl cancer res network phase II trial. Proc Am Soc Clin Oncol. 2005;23 (Suppl. 16) Abstract 6577.
50. Radford JA, Ketterer N, Sebban C. Ibritumomab tiuxetan (Zevalin TM) therapy is feasible and safe for the treatment of patients with advanced B-cell follicular lymphoma: Interim analysis for safety of a multicenter, phase III clinical trial. Blood. 2003;102 Abstract 1484.
51. 90Y ibritumomab tiuxetan (Zevalin) and rituximab in patients with previously-untreated follicular non-Hodgkin lymphoma (NHL). Blood. 2005;106(11) Abstract 2449.
52. 90Y) ibritumomab tiuxetan (Zevalin) for previously untreated follicular lymphoma (FL) patients. Blood. 2005;106(11) Abstract 4763.
53. 90Y) ibritumomab tiuxetan (zevalin) for previously untreated elderly diffuse large B-cell lymphoma (DLBCL) patients. Blood. 2005;106(11) Abstract 4765.
54. 90Y-Zevalin) radioimmunotherapy (RIT). Blood. 2005;106(11) Abstract 2453.
55. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219-1224.
56. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: A multivariable cohort analysis. Blood. 2003;102:2351-2357.
57. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934-2942.
58. 90Y) ibritumomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkins lymphoma (NHL). Blood. 2004;104(11) Abstract 897.
59. Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood. 2005;106:2896-2902.
60. 90Y ibritumomab tiuxetan (Zevalin, 90YZ) doses higher than 0.4 mCi/kg may be safely combined with high-dose BEAM and autotransplant: The role of dosimetry. Blood. 2004;104(11) Abstract 1162.
61. 90Y ibritumomab tiuxetan with high dose chemotherapy in elderly patients with non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol. 2005;23 (Suppl. 16) Abstract 6656.
62. Shimoni A, Zwas T, Oksman Y, et al. Ibritumomab tiuxetan (Zevalin) in the conditioning regimen for autologous and reduced-intensity allogeneic stem-cell transplantation in patients with chemo-refractory non-Hodgkin's lymphoma. Blood. 2005;106(11) Abstract 1131.
63. 90Yttrium ibritumomab tiuxetan) Treatment with PBSC support in refractory-resistant NHL patients: Preliminary results of a phase I/II study. Blood. 2005;106(11) Abstract 488.